AR016263A1 - Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio - Google Patents

Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio

Info

Publication number
AR016263A1
AR016263A1 ARP990102132A ARP990102132A AR016263A1 AR 016263 A1 AR016263 A1 AR 016263A1 AR P990102132 A ARP990102132 A AR P990102132A AR P990102132 A ARP990102132 A AR P990102132A AR 016263 A1 AR016263 A1 AR 016263A1
Authority
AR
Argentina
Prior art keywords
cell
expression
homologally
dna
construction
Prior art date
Application number
ARP990102132A
Other languages
English (en)
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of AR016263A1 publication Critical patent/AR016263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un constructo de ADN que altera la expresion de un gen G-CSF endogeno en una célula de mamífero en la integracion al genoma de la célula a través derecombinacion homologa, que el constructo comprende: (i) una secuencia objetivo seleccionado que contiene por lo menos 20 nucleotidos contiguos de la SEQ IDNO.: 5 y (ii) una secuencia reguladora de transcripcion, una célula recombinante homologamente establemente transfectada con el constructo de ADN, un métodode alteracion de la expresion del gen G-CSF endogeno en una célula de mamífero, uso de dicha célula para la manufactura de un medicamento, unmétodo de produccion de G-CSF y una molécula de ácido nucleico aislado.
ARP990102132A 1998-05-07 1999-05-06 Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio AR016263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8464998P 1998-05-07 1998-05-07

Publications (1)

Publication Number Publication Date
AR016263A1 true AR016263A1 (es) 2001-06-20

Family

ID=22186313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102132A AR016263A1 (es) 1998-05-07 1999-05-06 Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio

Country Status (18)

Country Link
US (2) US6242218B1 (es)
EP (1) EP1075530A1 (es)
JP (1) JP2002513579A (es)
KR (1) KR20010071207A (es)
CN (1) CN1308680A (es)
AR (1) AR016263A1 (es)
AU (1) AU762969B2 (es)
CA (1) CA2328476A1 (es)
CZ (1) CZ299460B6 (es)
GC (1) GC0000172A (es)
HU (1) HUP0101355A3 (es)
IL (1) IL139431A0 (es)
NO (1) NO20005586L (es)
NZ (1) NZ507451A (es)
PL (1) PL344391A1 (es)
TR (1) TR200003272T2 (es)
WO (1) WO1999057291A1 (es)
ZA (1) ZA200005744B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
JP2002017357A (ja) * 2000-07-04 2002-01-22 Calpis Co Ltd アンカーペプチド、融合蛋白質、及び蛋白質の固定化方法
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
JP5570677B2 (ja) 2002-04-25 2014-08-13 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド α−ガラクトシダーゼＡ欠損症の治療
JP4896745B2 (ja) * 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
JP2011518555A (ja) * 2008-04-14 2011-06-30 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的組込みのための線形ドナーコンストラクト
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery

Also Published As

Publication number Publication date
CN1308680A (zh) 2001-08-15
IL139431A0 (en) 2001-11-25
AU762969B2 (en) 2003-07-10
US6242218B1 (en) 2001-06-05
CZ20003807A3 (cs) 2001-04-11
HUP0101355A2 (hu) 2001-08-28
WO1999057291A1 (en) 1999-11-11
CZ299460B6 (cs) 2008-08-06
NZ507451A (en) 2003-12-19
ZA200005744B (en) 2001-05-16
CA2328476A1 (en) 1999-11-11
TR200003272T2 (tr) 2001-03-21
EP1075530A1 (en) 2001-02-14
AU3788799A (en) 1999-11-23
HUP0101355A3 (en) 2003-08-28
KR20010071207A (ko) 2001-07-28
NO20005586D0 (no) 2000-11-06
PL344391A1 (en) 2001-11-05
GC0000172A (en) 2006-03-29
US20030022850A1 (en) 2003-01-30
JP2002513579A (ja) 2002-05-14
NO20005586L (no) 2001-01-03

Similar Documents

Publication Publication Date Title
Kanopka et al. Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA
CN115651927B (zh) 编辑rna的方法和组合物
US20220275359A1 (en) Guide rna for editing target, with functional nucleotide sequence added
Okada et al. SINEs and LINEs share common 3′ sequences: a review
Kaufman et al. Translational control mediated by eucaryotic initiation factor-2 is restricted to specific mRNAs in transfected cells
KR102455623B1 (ko) CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도
KR20220004674A (ko) Rna를 편집하기 위한 방법 및 조성물
AR016263A1 (es) Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio
ES2543730T3 (es) Sistema mejorado de expresión de proteína
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ES2066759T3 (es) Regulador antisentido de la expresion de un gen en celulas de plantas.
Opalenik et al. The HIV-1 TAT protein induces the expression and extracellular appearance of acidic fibroblast growth factor
KR102690083B1 (ko) CRISPR/Cas12f1 시스템 효율화를 위한 U-rich tail을 포함하는 엔지니어링 된 가이드 RNA 및 그 용도
US20230374456A1 (en) T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy
BR9912498A (pt) Expressão de peptìdios eucarióticos em plastìdio de plantas
Sargsyan et al. Genomic organization and promoter characterization of the gene encoding a putative endoplasmic reticulum chaperone, ERp29
Bannwarth et al. Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line
US20230374500A1 (en) Engineered guide rna comprising u-rich tail for optimized crispr/cas12f1 system and use thereof
AR016262A1 (es) Una construccion de adn que altera la expresion de un gen pshbeta endogeno, una celula homologamente recombinante, un metodo para alterar la expresion dela fshbeta endogeno en la celula de un mamifero, uso de dicha celula para la manufactura de un medicamento, un metodo para producir fshbeta y una m
US20230383253A1 (en) Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy
US20240173432A1 (en) Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SluCas9
Joyner et al. Retrovirus long terminal repeats activate expression of coding sequences for the herpes simplex virus thymidine kinase gene.
Mártensson et al. Pre-B cell-specific λ5 gene expression due to suppression in non pre-B cells
Chattopadhyay et al. Two separate domains within vesicular stomatitis virus phosphoprotein support transcription when added in trans.
Botelho et al. The genomic structure of SYCP3, a meiosis-specific gene encoding a protein of the chromosome core

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal